- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 30, 2019
Distillery Therapeutics
Syntrix's dual CXCR1/CXCR2 inhibitor for combos in oral, lung cancers
BioCentury | Apr 13, 2018
Targets & Mechanisms
Meeting the burden
New developments in TMB, synthetic lethality, oncolytic viruses & more at AACR18
BioCentury | Jun 30, 2016
Distillery Therapeutics
Therapeutics: Chemokine CXC motif ligand 1 (CXCL1; GRO; MGSA); CXC chemokine receptor 1 (CXCR1); CXCR2 (IL8RB)
Items per page:
1 - 10 of 10